Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 7/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.43 |
| ▸ | PDE2A | O00408 | 1/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.43 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | NT5E | P21589 | 4/20 | 0.38 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21511191 | 1.00 | ADORA3 (0.43) | ADORA3ADORA2APDE2AADORA1ADRA1A | |
| SCHEMBL19987356 | 1.00 | ADORA3 (0.43) | ADORA3ADORA2APDE2AADORA1ADRA1A | |
| SCHEMBL19987331 | 0.86 | ADORA3 (0.59) | ADORA3ADORA2APDE2AADORA1ADRA1A | |
| SCHEMBL19974382 | 0.86 | ADORA3 (0.59) | ADORA3ADORA2APDE2AADORA1ADRA1A | |
| SCHEMBL19974375 | 0.78 | ADORA2A (0.45) | ADORA3ADORA2APDE2AADORA1ADRA1A | |
| SCHEMBL19987257 | 0.78 | ADORA2A (0.45) | ADORA3ADORA2APDE2AADORA1ADRA1A | |
| SCHEMBL19987188 | 0.78 | ADORA3 (0.61) | ADORA3ADORA2AADORA1NT5EADORA2B | |
| SCHEMBL19974379 | 0.78 | ADORA3 (0.61) | ADORA3ADORA2AADORA1NT5EADORA2B | |
| SCHEMBL750005 | 0.78 | ADORA3 (0.47) | ADORA3ADORA2APDE2AADORA1ADRA1A | |
| SCHEMBL750004 | 0.78 | ADORA3 (0.47) | ADORA3ADORA2APDE2AADORA1ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11453695-B2 | Nucleoside analogues and methods of use thereof | LCB PHARMA INC. (CA) | 2022-09-27 | — | — | US | disclosed |
| US-20190322693-A1 | NUCLEOSIDE ANALOGUES AND METHODS OF USE THEREOF | LCB PHARMA INC. (CA) | 2019-10-24 | — | — | US | disclosed |
| WO-2018049535-A1 | NUCLEOSIDE ANALOGUES AND METHODS OF USE THEREOF | LCB PHARMA INC. (CA) | 2018-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190322693-A1 | NUCLEOSIDE ANALOGUES AND METHODS OF USE THEREOF | PNP, TYMP, MTAP | ADORA3 156/4885ADORA2A 146/4885PDE2A 2895/4885 |
| US-11453695-B2 | Nucleoside analogues and methods of use thereof | PNP, RNGTT, MTAP | ADORA3 199/4885ADORA2A 216/4885PDE2A 3085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.